Stockscreener 앱 받기
59.02
1.58%
-0.95
전일 마감가:
$59.97
열려 있는:
$59.82
하루 거래량:
1.68M
Relative Volume:
0.67
시가총액:
$7.27B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
19.54
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
+1.34%
1개월 성능:
+11.53%
6개월 성능:
+4.20%
1년 성능:
+7.21%
1일 변동 폭
$58.53
$60.27
1주일 범위
$57.67
$61.75
52주 변동 폭
$42.01
$70.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
59.02 | 7.39B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
How many analysts rate Halozyme Therapeutics Inc. as a “Buy”Track top-performing stocks effortlessly - jammulinksnews.com
What analysts say about Halozyme Therapeutics Inc. stockDiscover stock picks with superior returns - jammulinksnews.com
What catalysts could drive Halozyme Therapeutics Inc. stock higher in 2025Unmatched profit potential - jammulinksnews.com
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Halozyme Therapeutics Insider Lowered Holding By 38% During Last Year - 富途牛牛
Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT - MSN
How Halozyme Therapeutics Inc. stock performs during market volatilitySmart Money Tracking Signal Generator Activated - metal.it
Short Interest Drops in Halozyme Therapeutics Inc. After RallyOversold Recovery Opportunity Stocks Attract Buyers - metal.it
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Halozyme Therapeutics Inc. Outperforms Peers on Volume MetricsPrice Action Based Buy Opportunity List Published - metal.it
Why Halozyme Therapeutics Inc. stock attracts strong analyst attentionProfit Target Stock Opportunity Monitor Activated - metal.it
How Resilient Is Halozyme Therapeutics Inc. Stock During Economic DownturnsMarket Entry and Exit Point Tips From Traders - metal.it
Published on: 2025-07-28 01:53:45 - jammulinksnews.com
Does Halozyme Therapeutics Inc. stock perform well during market downturnsBuild a strong portfolio for growth and safety - jammulinksnews.com
What is Halozyme Therapeutics Inc. company’s growth strategyOutstanding capital returns - jammulinksnews.com
Halozyme’s Promising Cancer Study: A Potential Game-Changer in Oncology - TipRanks
Should I buy Halozyme Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com
What risks could impact Halozyme Therapeutics Inc. stock performanceConsistently superior profits - jammulinksnews.com
38% Of This Halozyme Therapeutics Insider's Holdings Were Sold - simplywall.st
Is Halozyme Therapeutics Inc. stock overhyped or has real potentialBreakout profit opportunities - jammulinksnews.com
Halozyme to Report Second Quarter 2025 Financial and Operating Results - Eastern Progress
BlackRock, Inc. Adjusts Holdings in Halozyme Therapeutics Inc. - GuruFocus
Halozyme Therapeutics Inc. Stock Analysis and ForecastExceptional profit margins - Autocar Professional
Halozyme Therapeutics Says Myeloma Drug With Enhanze Delivery Technology Gets EU Approval - 富途牛牛
Is Halozyme Therapeutics Inc. a good long term investmentFree Risk Assessment Services - jammulinksnews.com
J&J Darzalex injectable cleared in EU for smouldering MM (JNJ) - Seeking Alpha
Halozyme says EU approves new indication for Janssen’s Darzalex Faspro - TipRanks
Breakthrough: EU Approves DARZALEX Faspro as First-Ever Treatment for Early-Stage Multiple Myeloma - Stock Titan
What drives Halozyme Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock - Yahoo Finance
Halozyme to Present Q2 2025 Financial Results After Market Close on August 5 - Stock Titan
Halozyme Stock Maintains Hold Rating Amid CMS Pricing Uncertainty and Regulatory Concerns. - AInvest
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.15%
자본화:
|
볼륨(24시간):